Sibannac Takes Majority Stake in Apollo Wellness Centers
Sibannac has not acquired Doc-Rx, which remains its partner in the Apollo joint venture.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sibannac (SNNC) holds a 51% controlling interest in Apollo Wellness Centers, a joint venture formed with Doc-Rx.com.
The venture operates under an agreement dated October 1, 2026, and has access to Doc-Rx's existing telehealth, partner compounding pharmacies and health-tracking platform for licensed professional use. Apollo expects its largest revenue source to be clinics operating under the Apollo Wellness Centers brand. Each clinic would be owned by a licensed prescriber who licenses the brand and orders through Doc-Rx, allowing expansion without the venture owning each location.
Apollo also plans to develop its own peptides, nutraceuticals and medical foods, alongside expanded telemedicine services. These are development plans rather than announced product launches or clinic openings.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point51% ownership gives Sibannac control of Apollo Wellness Centers, its joint venture with Doc-Rx.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Apollo plans licensed wellness clinics, expected to become its largest revenue source without owning each location.
- Minor pointApollo has access to Doc-Rx's existing operating platform for licensed professional use.
- Minor point. Forward-looking: it has not happened yet and may not happen.Apollo plans its own product line of peptides, nutraceuticals and medical foods.
- Minor point. Forward-looking: it has not happened yet and may not happen.Apollo plans expanded telemedicine services.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARADISE VALLEY, AZ / ACCESS Newswire / October 27, 2026 / Sibannac, Inc. (OTC PINK:SNNC) today announced that it holds a
Apollo begins with access to the platform Doc-Rx already operates: telehealth, partner 503A compounding pharmacies, peptides made in the United States from raw material to finished product, and health tracking, all for licensed professional use. Apollo's main growth plan is to stand up wellness clinics under the Apollo Wellness Centers brand.
A controlling stake in a venture with a working platform. Sibannac's
Built on Doc-Rx. Doc-Rx provides HIPAA-protected telehealth in which licensed clinicians meet patients online and prescribe. Prescriptions are filled through Doc-Rx's partner 503A compounding pharmacies, which keep each step of making their peptides inside the United States, from domestic raw materials through synthesis and compounding. The platform also includes health tracking.
Wellness clinics through licensing. Apollo expects its largest source of revenue to be wellness clinics under the Apollo Wellness Centers brand. Each clinic would be owned by a licensed prescriber who licenses the Apollo Wellness Centers brand and orders through Doc-Rx. The model is intended to let the brand grow without the joint venture owning each location.
A product line over time. Apollo also plans to develop its own line of peptides, nutraceuticals and medical foods, along with expanded telemedicine services.
"Apollo gives Sibannac a controlling position in medically supervised wellness care, built on a platform that is already operating," said David Mersky, CEO of Sibannac, Inc. "Doc-Rx brings telehealth, partner pharmacies and a U.S. supply chain for peptides. Our focus now is putting that platform to work in Apollo Wellness Centers clinics."
"Doc-Rx built its platform so licensed clinicians could prescribe with confidence in where their products come from," said Shawn Stephens, Managing Director of Doc-Rx.com, LLC "Apollo is a way to bring that platform to clinics under one brand."
More information
Shareholders and the investment community can learn more about Apollo Wellness Centers at www.snncinc.com/apollo. Sibannac's filings and investor information are available at snncinc.com/investors.
Licensed prescribers interested in opening an Apollo location can contact info@apollowc.com.
About the companies
About Sibannac, Inc. Sibannac, Inc. (OTCID:SNNC) is a plant-medicine and wellness company advancing research, cultivation and therapeutic applications for mental health and wellness, and building compliant assets and strategic partnerships. [Replace with Sibannac's current boilerplate, adding the Apollo sentence.] Sibannac holds a
About Doc-Rx.com, LLC Doc-Rx operates a HIPAA-protected telehealth platform for licensed professionals. It partners with U.S.-based 503A compounding pharmacies and offers U.S.-made peptides and health tracking. Learn more at doc-rx.com.
About Apollo Wellness Centers, Inc. Apollo Wellness Centers, Inc. is a joint venture of Sibannac, Inc. and Doc-Rx.com, LLC. It plans to stand up wellness clinics under the Apollo Wellness Centers brand, licensed to and owned by licensed prescribers and built on the Doc-Rx platform.
Forward-Looking Statements
This press release contains forward-looking statements. They include statements about the plans, objectives, expected activities and benefits of Apollo Wellness Centers, Inc. and its joint venture partners, Sibannac, Inc. and Doc-Rx.com, LLC. Examples are plans to stand up wellness clinics under the Apollo Wellness Centers brand through a licensing model; the expectation that these clinics will be the joint venture's largest source of revenue; the revenue the joint venture expects to earn under its agreement; and plans to develop an Apollo line of peptides, nutraceuticals and medical foods. Words such as "plans," "intends," "expects," "aims," "designed to," "will" and similar expressions identify forward-looking statements.
These statements are based on current expectations and assumptions. They are not guarantees of future results, and actual results may differ materially. Factors that could cause differences include: the joint venture's ability to find and retain licensed prescribers to own and operate clinics, and to open clinics on the expected timeline or at all; whether the joint venture generates the revenue contemplated by its agreement, or any revenue or profit, and how much of any benefit accrues to Sibannac; the terms of the joint venture agreement, including Doc-Rx's rights as minority partner; Sibannac's ability to meet its obligations to the joint venture, including any funding; franchise, business opportunity and licensing laws that may apply to the licensing model; reliance on Doc-Rx's platform and on the independent compounding pharmacies it partners with; federal and state laws governing compounding pharmacies, the practice of medicine and peptide products, including any change in how the FDA or state authorities treat particular peptides; the need for additional capital; competition; and the other risks described in Sibannac's disclosure statements and reports posted on OTC Markets (otcmarkets.com).
Forward-looking statements speak only as of the date of this release. Except as required by law, Sibannac undertakes no obligation to update or revise any forward-looking statement.
Contacts
Investor relations: Sibannac, Inc. · investors@sibannacinc.com
Media: media@snncinc.com · www.snncinc.com · x.com/sibannacinc
Clinic and licensing inquiries: Apollo Wellness Centers · info@apollowc.com
SOURCE: Sibannac, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much of Apollo Wellness Centers does Sibannac (SNNC) own?
Sibannac holds a 51% controlling interest in Apollo Wellness Centers. Apollo is a joint venture with Doc-Rx.com under an agreement dated October 1, 2026; Sibannac has not acquired Doc-Rx.
How does Sibannac's Apollo Wellness Centers clinic model work?
Each Apollo clinic would be owned by a licensed prescriber who licenses the Apollo Wellness Centers brand and orders through Doc-Rx. Apollo expects these clinics to be its largest source of revenue, using a model that does not require the joint venture to own each location.